If you’ve been living with vaginal dryness, pain during sex, or repeat urinary tract infections since menopause, vaginal estrogen is one of the most effective treatments available, and one of the least often offered. It’s a low dose of estrogen placed directly on the tissue that needs it. Because so little of it reaches the rest of your body, it works differently than the estrogen pills or patches used for hot flashes.
One important thing to know up front: vaginal estrogen does not treat hot flashes. That mix-up causes more confusion than almost anything else about this treatment, so it’s worth being clear from the start.
What It Treats
After menopause, falling estrogen levels cause the tissue of the vulva, vagina, urethra, and bladder to thin, lose elasticity, and get less blood flow. Doctors call this collection of changes genitourinary syndrome of menopause, or GSM for short. Common symptoms include dryness, burning, itching, pain during sex, urinary urgency, and repeat urinary tract infections.
Unlike hot flashes, these symptoms usually don’t fade on their own with time. Because the tissue change is ongoing, symptoms often get worse in the years after your last period rather than better.
GSM affects a large share of postmenopausal women, and only a small fraction are ever treated for it. The reasons are familiar: it doesn’t get asked about at appointments, and it’s a difficult thing to raise unprompted. Neither of those is a medical reason to go without treatment.
Your Options
- Cream. Applied with an applicator daily for a short start-up period, then just a few times a week.
- Tablet or softgel insert. Placed in the vagina with a small applicator a few times a week; less messy than cream.
- Ring. A soft, flexible ring inserted into the vagina that releases estrogen continuously; replaced only once every three months.
All three work about equally well. Cost, insurance coverage, and personal preference usually decide which one is right for you.
A practical note on the cream. It can also be applied to the vulva and around the opening of the vagina. That’s where a lot of the discomfort actually sits. If dryness and burning on the outside are your main complaint, mention that, because it can influence which option suits you best.
Why It’s Different From Systemic Hormone Therapy
At the low doses used for these symptoms, very little estrogen enters your bloodstream. Levels stay close to what’s normal after menopause. That’s why medical guidelines treat low-dose vaginal estrogen differently from estrogen pills or patches, and why it carries a different risk conversation.
If you have a uterus and take estrogen pills or patches, you also need a progestogen to protect the uterine lining. With low-dose vaginal estrogen, that extra medication usually isn’t needed, because so little estrogen reaches the rest of your body. That said, any vaginal bleeding after menopause should always be checked out by your provider, whether or not you’re using vaginal estrogen.
It Can Also Help With UTIs
Vaginal estrogen has real evidence behind it for cutting down repeat urinary tract infections after menopause. It’s thought to work by restoring a healthier vaginal environment. That includes a lower pH, which supports good bacteria and makes it harder for infection-causing bacteria to take hold. This benefit gets overlooked often. Repeat UTIs tend to be treated as a separate urinary problem, rather than connected to the same hormone-driven tissue changes.
If you’ve been through several rounds of antibiotics for UTIs since menopause, this is worth raising specifically. It’s a different approach than treating each infection as it arrives.
A 2026 Update to the Warning Label
In February 2026, the FDA approved label changes for the first group of menopausal hormone therapy products, including topical vaginal estrogen. The change removed statements about cardiovascular disease, breast cancer, and probable dementia from the boxed warning. That’s the strongest type of safety warning on a drug label.
It’s important to understand what this does and doesn’t mean: the underlying research didn’t change, only the labeling did. Risk information is still described elsewhere on the label, and your provider will still walk through your personal risks and benefits with you.
The FDA announced its intention in November 2025. The change applies to the first six products approved, with more following as manufacturers submit them. So you may still see the older warning on a package for some time.
The 2026 label change
In February 2026 the United States Food and Drug Administration approved labeling changes to the first group of menopausal hormone therapy products. The changes removed statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning. The category of topical vaginal estrogen was included.
The agency had begun the review in November 2025, and further manufacturers’ labels have been processed since.
What changed was the labeling, not the underlying trial data. Risks continue to be described in the body of the label, and individual assessment still applies.
If You’ve Had Breast Cancer
Most observational studies of women with a history of breast cancer using vaginal estrogen have not found a higher overall risk of the cancer coming back. That evidence comes from observational studies rather than randomized trials, so it has some built-in limits. One large study from Denmark did find a higher recurrence rate in one group. Those were women taking a type of breast cancer medication called an aromatase inhibitor. The same study did not find a higher death rate in that group.
These decisions are made one-on-one, usually together with your oncology team. Non-hormonal moisturizers and lubricants are typically tried first in this situation.
What Else Can Help
Vaginal estrogen isn’t the only option, and some women use more than one thing.
Non-hormonal vaginal moisturizers are used regularly, every few days, to keep tissue comfortable. Lubricants are used at the time of sex and do a different job. Water-based and silicone-based lubricants are both widely available; silicone lasts longer but shouldn’t be used with silicone toys.
There’s also a vaginal DHEA insert (prasterone) and an oral tablet called ospemifene, both approved in the U.S. for painful sex due to menopause. If vaginal estrogen isn’t suitable or isn’t working, these are reasonable things to ask about.
What to Expect
Most people notice improvement within a few weeks, with fuller benefits by around twelve weeks. Low estrogen is an ongoing condition, not a one-time event. So symptoms tend to return if treatment stops. That’s why this is usually a long-term therapy.
Mild irritation or discharge in the first few weeks is common and usually settles. If discomfort is significant, or if you have any bleeding, contact your provider rather than stopping and assuming it isn’t for you.
No. Low-dose vaginal estrogen works on the tissue it’s applied to. Some women use both a vaginal treatment and a whole-body treatment, because they address different things.
Usually not, because so little estrogen reaches the rest of your body at these doses. Any bleeding after menopause should still be reported.
Typically ongoing. The underlying cause is the low estrogen state, which doesn’t reverse, so symptoms tend to come back within a few months of stopping.
Transfer to a partner is minimal at these doses. A practical approach is to avoid applying cream immediately before sex, and to wash hands after application.
Yes, and it’s common. Whole-body hormone therapy doesn’t always fully resolve vaginal and urinary symptoms, and adding a local treatment alongside it is standard practice.
Write it down and hand it over, or send it through the patient portal beforehand. Providers do not find this awkward, and a written note gets past the moment of hesitation that stops a lot of women from being treated.
Bottom Line
Vaginal estrogen is a well-studied, low-risk option for the dryness, discomfort, and urinary symptoms that often show up after menopause, even though it won’t help with hot flashes. If any of these symptoms sound familiar, it’s worth bringing up with your provider. This is a common, treatable part of menopause, not something you have to simply live with.
